| Date Filed | Type | Description |
| 09/27/2023 |
8-K
| Quarterly results |
| 08/23/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 08/14/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/07/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 08/01/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 07/20/2023 |
8-K
| Quarterly results |
| 07/17/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 05/25/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 05/18/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/18/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data|
Docs:
|
"NanoVibronix Issues Letter to Shareholders ELMSFORD, N.Y., May 18, 2023 — NanoVibronix, Inc ., , a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave Portable Ultrasonic Therapeutic Devices, today issued a letter to shareholders from its Chief Executive Officer, Brian Murphy, providing a review of the first quarter 2023 and recent business developments. To Our Shareholders: NanoVibronix is committed to our strategic vision of commercializing our distinct and effective therapies, which we believe enable healthcare providers to treat patients in need, fill a void in the market and have the potential to increase value for our shareholders. We are focused on several areas, which we believe will have a substantial impact on our growth and pro..." |
|
| 05/01/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/01/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/01/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/19/2023 |
8-K
| Quarterly results |
| 04/17/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/31/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 03/28/2023 |
8-K
| Quarterly results |
| 03/14/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 03/03/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 02/22/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 02/08/2023 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea... |
| 01/18/2023 |
8-K
| Quarterly results |
| 01/05/2023 |
4
| MIKA THOMAS (Director) has filed a Form 4 on NanoVibronix, Inc.|
Txns:
| Bought 50,000 shares
@ $0.25, valued at
$12.5k
|
|
| 12/15/2022 |
8-K
| Quarterly results |
| 12/01/2022 |
8-K
| Quarterly results |
| 11/30/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 11/29/2022 |
8-K
| Quarterly results |
| 11/16/2022 |
8-K
| Quarterly results |
| 11/15/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/31/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 10/31/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 10/19/2022 |
8-K
| Quarterly results |
|